Publications
AnaemiaWorld brings you the latest results from trials, reviews, editorials and opinion pieces. Scroll down for some of the latest and most exciting publications on renal anaemia and chronic kidney disease.
Chronic kidney disease and renal anaemia background
2007
Ofsthun N, et al.
Impact of the Change in CMS Billing Rules for Erythropoietin on Hemoglobin Outcomes in Dialysis Patients
Blood Purif. 2007;25(1):31-5. Epub 2006 Dec 14
2007 Oct
Fishbane S & Nissenson AR
The new FDA label for erythropoietin treatment: how does it affect haemoglobin target?
Kidney Int. 2007 Oct;72(7):806-13. Epub 2007 Jun 27
2007 Feb
Disney A et al.
Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study.
Nephrology (Carlton). 2007 Feb;12(1):95-101
2006 Dec
Schmitt C, et al.
Increased injection pain with darbepoetin-{alpha} compared to epoetin-{beta} in paediatric dialysis patients.
Nephrol Dial Transplant. 2006 Dec;21(12):3520-4. Epub 2006 Aug 25
2006 Nov-Dec
Messana T
Erythropoietin claims monitoring policy: implications of the October 2006 update.
Nephrol Nurs J. 2006 Nov-Dec;33(6):660-3; quiz 664-5
2006 Oct
Schiesser D, et al.
Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Nephrol Dial Transplant. 2006 Oct;21(10):2841-5. Epub 2006 Aug 5
2006 Oct
Hoggard J et al
Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Curr Med Res Opin. 2006 Oct;22(10):2023-30
2006 Sep-Oct
Lorber D, et al.
Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
Endocr Pract. 2006 Sep-Oct;12(5):506-13
2006
Sarac E, et al.
Clinical Outcomes Associated with Conversion from Epoetin alfa to Darbepoetin alfa in Hospitalized Hemodialysis Patients.
Am J Nephrol. 2006;26(6):571-8. Epub 2006 Dec 14
2006 Jul-Aug
Mccarley P
The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses.
Nephrol Nurs J. 2006 Jul-Aug;33(4):423-6, 445; quiz 427-8
2006 Jun
Roberts T, et al.
Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels.
Nephrol Dial Transplant. 2006 Jun;21(6):1652-62. Epub 2006 Jan 31
2006 May
Papatheofanis F, et al.
Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Curr Med Res Opin. 2006 May;22(5):837-42
2005 Aug
Provenzano R et al
Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Clin Nephrol. 2005 Aug;64(2):113-23
2005 May
Tolman C et al.
Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.
J Am Soc Nephrol. 2005 May;16(5):1463-70. Epub 2005 Mar 23
2005 May
Ling B, et al.
Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
Clin Nephrol. 2005 May;63(5):327-34
2005 Mar
Mix T, et al.
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patientswith chronic kidney disease.
Am Heart J. 2005 Mar;149(3):408-13
2005 Jan
El Nahas AM, Bello AK
2004 Jul
Pisoni et al
Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS).
Am J Kidney Dis. 2004 Jul;44(1):94-111
Guide line
2007
KDOQI
National Kidney Foundation releases anemia guideline update. New recommendations based on months of analysis of six new randomized trials.
(Online) NKF Newsroom, Orlando, FL, August 30, 2007.
In this section
Be the first to know
Subscribe to the latest publications, news and event announcements
